Repurposing existing drugs, such as rifaximin, can accelerate the development of new treatments because their safety profiles are already established. A recent study screened 3,800 FDA-approved drugs and identified rifaximin as a promising lead compound for PIM-1 inhibition.
The potential of rifaximin lies in its ability to disrupt PIM-1, potentially slowing or halting the progression of prostate cancer, especially in hormone-resistant cases. The established safety profile of rifaximin could simplify its transition into clinical trials, potentially broadening prostate cancer treatment strategies.
Androgen Receptor Activity (ARA) for BAT
Dual ARi in mCRPCa - Antonarakis = 'Combo of 2 AR-directed agents should not be utilized in clinical practice at this time', MedPage 7/20/23
China--Transforming the FDA and Leveling the Playing Field For Small Biotechs